top of page

AAO 2025 Sessions and Company Showcases

Orlando, Oct. 16
S1 – Do the Eyes Have It? Ophthalmic Commercial Dynamics and Investment Opportunities
S2 – Robotics in Ophthalmology From Vision to Reality
S3 – Oculomics- Can Ocular Diagnostics with AI Improve Systemic Disease Management
S4 – Strategic Pathways- Driving Value Through Ophthalmic Innovation and Acquisition
S5 - The Winning Pitch Challenge Intro.
S6 – Leadership Perspective on the Ophthalmology Ecosystem
4DMT
Adverum Biotechnologies
AAVantgarde Bio UK Limited
Annexin Pharmaceuticals AB
Ashvattha Therapeutics, Inc.
Astellas Pharma Global Development, Inc.
Aviceda Therapeutics
Bausch + Lomb
Dragonfleye Therapeutics Corp.
Emmecell
EyeBio
EyeDura Therapeutics
EyePoint
Heru
Ikarovec
Iolyx Therapeutics
Kiora Pharmaceuticals Inc.
Lightfield Medical
Long Bridge Medical
Nanoscope Therapeutics
Neurotech Pharmaceuticals, Inc.
Ocular Therapeutix
Oculis
ONL Therapeutics

(Sort and view by choosing a category below)

bottom of page